Unlocking the Potential of PEG3: A Zinc Finger and SCAN Domain-Containing Protein 24 as a Drug Target

Target Name: PEG3

NCBI ID: G5178

PEG3

Unlocking the Potential of PEG3: A Zinc Finger and SCAN Domain-Containing Protein 24 as a Drug Target

PEG3 (Zinc Finger and SCAN Domain-Containing Protein 24) is a protein that has garnered significant interest due to its unique structure and biology. It is a 24kDa protein that is composed of a zinc finger and a SCAN domain. The zinc finger is a conserved protein domain that is known for its ability to form aggregates, while the SCAN domain is a unique protein that is involved in the regulation of protein-protein interactions.

Recent studies have suggested that PEG3 may have the potential to serve as a drug target or biomarker. In this article, we will explore the biology and potential drug targets of PEG3.

The Biology of PEG3

PEG3 was first identified as a protein that is expressed in various tissues, including brain, heart, and muscle. It is characterized by a unique structure that consists of a zinc finger and a SCAN domain. The zinc finger is a conserved domain that is known for its ability to form aggregates, while the SCAN domain is a unique protein that is involved in the regulation of protein-protein interactions.

PEG3 functions as a negative regulator of the protein interaction between the SCAN domain and its target proteins. It does this by forming a covalent complex with the SCAN domain, which in turn inhibits the interaction between the SCAN domain and its target proteins. This unique mechanism of regulation has implications for the functions of PEG3 and suggests that it may have a wide range of potential drug targets.

Drug Targets for PEG3

The unique structure and function of PEG3 make it an attractive drug target. Several studies have suggested that PEG3 may serve as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the potential drug targets for PEG3 is cancer.PEG3 has been shown to play a negative role in the regulation of cell proliferation and has been shown to be involved in the development of various types of cancer. For example, studies have suggested that PEG3 may be a potential therapeutic target for breast cancer, ovarian cancer, and colon cancer.

Another potential drug target for PEG3 is neurodegenerative diseases.PEG3 has been shown to be involved in the regulation of neurotransmitter release and has been implicated in the development of various neurological disorders. For example, studies have suggested that PEG3 may be a potential therapeutic target for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

PEG3 may also serve as a potential drug target for autoimmune diseases. Studies have suggested that PEG3 may be involved in the regulation of immune cell function and has been implicated in the development of autoimmune diseases. For example, studies have suggested that PEG3 may be a potential therapeutic target for rheumatoid arthritis, lupus, and other autoimmune diseases.

The Potential of PEG3 as a Biomarker

PEG3 may also have the potential to serve as a biomarker for various diseases. Its unique structure and function make it an attractive candidate for use as a biomarker.

One of the potential applications of PEG3 as a biomarker is its ability to be targeted by small molecules. The zinc finger and SCAN domain of PEG3 can be modified with small molecules, which can then be used to interact with the protein and be detected in the body. This approach has the potential to be a powerful tool for the development of diagnostic tests for various diseases.

Another potential application of PEG3 as a biomarker is its ability to be used as a therapeutic target. By modifying the zinc finger and SCAN domain of PEG3 with small molecules, it is possible to target the protein and inhibit its function

Protein Name: Paternally Expressed 3

Functions: Induces apoptosis in cooperation with SIAH1A. Acts as a mediator between p53/TP53 and BAX in a neuronal death pathway that is activated by DNA damage. Acts synergistically with TRAF2 and inhibits TNF induced apoptosis through activation of NF-kappa-B (By similarity). Possesses a tumor suppressing activity in glioma cells

The "PEG3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PEG3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets